At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
IMMX Immix Biopharma, Inc.
Pre-Market Trading 12-23 06:35:41 EST
2.17
-0.05
-2.25%
High2.32
Low2.09
Vol79.91K
Open2.22
D1 Closing2.22
Amplitude10.36%
Mkt Cap59.69M
Tradable Cap34.64M
Total Shares27.51M
T/O173.36K
T/O Rate0.50%
Tradable Shares15.96M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
BRIEF-Immix Biopharma Announces Positive U.S. Clinical Data From First Four Patients In Nexicart-2 U.S. Trial
Immix Biopharma Announces Positive U.S. Clinical Data From First Four Patients in Nexicart-2 U.S. Trial of Sterically-Optimized CAR-T Nxc-201 in Relapsed/Refractory Light Chain (Al) Amyloidosis
Immix Biopharma Announces 75% Complete Response Rate (N=16); 31.5 Months Best Response Duration (Ongoing) for CAR-T Nxc-201 in Relapsed/Refractory Al Amyloidosis Patients at Ash 2024
Immix Biopharma Announces DR. Raymond Comenzo, Internationally Recognized Al Amyloidosis Expert, Director of the Myeloma and Amyloid Program at Tufts Medical Center, Joins Scientific Advisory Board
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and immune-dysregulated diseases in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and colorectal cancer; and NXC-201 for relapsed/refractory multiple myeloma. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.